Table 2.
Summary of characteristics for studies investigating systemic treatment and radiotherapy
| Indication | Source | Study design | Dataset (dates) | Median age (years) | Stage | Other study details | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Systemic treatment | ||||||||||
| Neoadjuvant chemotherapy, bladder | Chu 201913 | Retrospective observational comparison | SEER Medicare database (2004-2012) | 72.9 (mean) | II | Same study as Chu 201913 bladder surgery | ||||
| Adjuvant chemotherapy, bladder | Corbett 201927 | Retrospective observational comparison | NCDB (2006-2013) | NR | pT3-T4 or pN+ | — | ||||
| Booth 201428 | Retrospective observational comparison | OCR | 38% were ≥70 | 18% <T3, 82% T3-T4, 68% node positive | — | |||||
| Neoadjuvant chemotherapy, breast | Sanford 201629 | Retrospective observational comparison | Research database at University of Texas (1995-2007) | 50 (range 24-83) | I-III (clinical) | Time from end of neoadjuvant chemotherapy to surgery | ||||
| Adjuvant chemotherapy, breast | Gagliato 201430 | Retrospective observational comparison | MD Anderson Cancer Center institutional database. (1997-2011) | 50 (range 19-85) | I-III | — | ||||
| Mateo 202020 | Retrospective observational comparison | NCDB (2010-2014) | NR | I-III | — | |||||
| Hershman 200631 | Retrospective observational comparison | SEER Medicare database (1992-1999) | NR | I-II | — | |||||
| Adjuvant chemotherapy, colon, rectum | Hershman 200632 | Retrospective observational comparison | SEER Medicare database (1992-1999) | NR | III Colon | — | ||||
| Cheung 200933 | Retrospective observational comparison | SEER Medicare database (1991-2002) | 73.3 (IQR 69.8-77.4) | II- III Rectal | — | |||||
| Bayraktar 201134 | Retrospective observational comparison | Jackson Memorial Hospital and University of Miami Sylvester Comprehensive Cancer Center (2000-2008) | 55.7±1.1 for ≤60 days and 56.9±1.8 for >60 days (mean±SE) | II-III Colon | — | |||||
| Lima 201135 | Retrospective observational comparison | Alberta Cancer Registry, ambulatory care classification system, discharge abstract database (2000-2005) | NR | III Colon | — | |||||
| Becerra 201736 | Retrospective observational comparison | New York State Registry, SPARCS (2004-2009) | NR | III Colon | — | |||||
| Turner 201837 | Retrospective observational comparison | NCDB (2006-2014) | NR | III Colon | — | |||||
| Xu 201438 | Retrospective observational comparison | SEER Medicare database (1992-2005) | 73.6 (IQR 69.8-77.6) | II Colon | — | |||||
| Massarweh 201539 | Retrospective observational comparison | NCDB (2003-2010) | 60.8 (±11.6) (mean (±SD)) | III Colon | — | |||||
| Adjuvant chemotherapy, NSCLC | Booth 201340 | Retrospective observational comparison | OCR (2004-2006) | 62 (28-85) (mean (range)) | I-IV (pathological) | — | ||||
| Salazar 201741 | Retrospective observational comparison | NCDB (2004-2012) | 64 (IQR 57-70) | I-III (pathological) | — | |||||
| Radiotherapy | ||||||||||
| Definitive radiotherapy/neoadjuvant, bladder | No high validity data found | |||||||||
| Adjuvant radiotherapy, post breast conserving surgery | Hébert-Croteau 200442 | Retrospective observational comparison | Random population based sample of five regions of Quebec, Canada for periods covering 1988-1994 | NR | I-II | — | ||||
| Neoadjuvant (chemo)radiation, rectum* | No high validity data found | |||||||||
| NSCLC, stage III chemoradiation | No high validity data found | |||||||||
| SCLC, limited stage chemoradiation | No high validity data found | |||||||||
| Adjuvant chemoradiation, cervix | Jhawar 201743 | Retrospective observational comparison | NCDB (2004-2013) | 46 (IQR 38-56) | IB1-IIIB | No stratified wait group table but adjusted analysis | ||||
| Definitive chemoradiation, cervix | No high validity data found | |||||||||
| Radical chemoradiation, head and neck | Sharma 201644 | Retrospective observational comparison | NCDB (2003-2006) | 57.6 (9.9) (mean (SD)) | III-IV (clinical, non-metastatic) | Oropharynx chemoradiation | ||||
| Adjuvant (chemo)radiation, head and neck | Harris 201845 | Retrospective observational comparison | NCDB (2004-2013) | 59 (10.9) (mean (SD)) | III-IV (non-metastatic) | Interaction between subsite and outcome observed | ||||
| Radical (chemo)radiation, nasopharyngeal carcinoma | Chen 201646 | Retrospective observational comparison | Sun Yat-Sen University Cancer Center, institutional series (2009-2012) | NR, 45% ≤45 (primary cohort) | I-IV (non-metastatic) | 99.6% World Health Organization histology type II/III, treated with IMRT | ||||
IMRT=intensity modulated radiation therapy; IQR=interquartile range; NCDB=National Cancer Database (US); NR=not reported; NSCLC=non-small cell lung cancer; OCR=Ontario Cancer Registry; SCLC=small cell lung cancer; SD=standard deviation; SE=standard error; SEER=Surveillance, Epidemiology, and End Results; SPARCS=Statewide Planning and Research Cooperative System.
*
Delay studies primarily investigating therapeutic benefit of usually short delay between completion of neoadjuvant treatment and surgery for rectal cancer are excepted. No high validity studies investigating time from diagnosis to start of neoadjuvant therapy were found for rectal cancer.